30 June 2020 15:00 BST
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 29 June 2020, it was notified by Pascal Soriot, Chief Executive Officer, that, on 29 June 2020, Mr Soriot ceased to be beneficially interested in 127,389 Ordinary Shares of $0.25 each in the Company, following the gift of those shares to family members for nil consideration.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
|1||Details of the person discharging managerial responsibilities / person closely associated|
|2||Reason for the notification|
|a)||Position/status||Chief Executive Officer|
|b)||Initial notification /Amendment||Initial notification|
|3||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|4||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)||Description of the financial instrument, type of instrument Identification code||Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292|
|b)||Nature of the transaction||Gift of shares to family members for nil consideration|
|c)||Price(s) and volume(s)||
|d)||Aggregated information - Aggregated volume - Price||Not applicable - single transaction|
|e)||Date of the transaction||29 June 2020|
|f)||Place of the transaction||Outside a trading venue|
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.